TAYSIDE PRESCRIBER



Tayside DTC Supplement No 77

March 2008

Produced by NHS Tayside Drug and Therapeutics Committee Medicines Advisory Group (MAG)

SMC Advice issued in February & March 2008

Medicine	Indication	Local recommendation category	Comments and useful links
Clobetasol propionate 0.05% shampoo (Etrivex [®]) - Abbreviated submission	Topical treatment of moderate scalp psoriasis in adults	Not recommended	<u>SMC advice</u>
Colesevelam hydrochloride (Cholestagel [®]) - <i>Non submission</i>	Hypercholesterolaemia with a statin or monotherapy	Not recommended	<u>SMC advice</u>
Daptomycin 350mg & 500mg vials (Cubicin [®])	Staphylococcus aureus bacteraemia associated with right sided infective endocarditis or skin and soft tissue infections	Pending AMG decision	<u>SMC advice</u> <u>SPC link</u>
Diclofenac 75mg/2ml injection (Dyloject [®])	Treatment or prevention of post- operative pain	HOSPITAL ONLY -pending specialist feedback	SMC advice
Follitropin alfa 150 IU/ lutropin alfa 75 IU for injection (Pergoveris [®]) - <i>Abbreviated submission</i>	Stimulation of follicular development in women with severe LH and FSH deficiency	HOSPITAL ONLY – Assisted Conception Unit	<u>SMC advice</u> <u>SPC link</u>
Fondaparinux sodium 2.5mg/0.5ml pre-filled syringe (Arixtra [®])	ST segment elevation myocardial infarction (STEMI)	HOSPITAL ONLY- pending specialist feedback	<u>SMC advice</u> <u>SPC link</u>
0.4% Glyceryl trinitrate rectal ointment (Rectogesic [®]) - <i>Third Resubmission</i>	Relief of pain associated with chronic anal fissure	Not recommended	<u>SMC advice</u>
Infliximab 100mg powder for infusion (Remicade [®])	Severe, active Crohn's disease in paediatric patients	HOSPITAL ONLY – medical paediatrics	<u>SMC advice</u> <u>SPC link</u>
Levetiracetam 250, 500, 750 & 100mg tablets and 100mg/ml oral solution (Keppra [®]) - <i>Resubmission</i>	Adjunctive therapy in partial onset seizures in children	GPs may prescribe under the direction of paediatrics	<u>SMC advice</u> <u>SPC link</u>
Levetiracetam 250, 500, 750 & 100mg tablets and 100mg/ml oral solution (Keppra [®]) - <i>Resubmission</i>	Adjunctive therapy in Juvenile Myoclonic Epilepsy (JME)	GPs may prescribe under the direction of paediatrics or adult neurology. TAPG review June 08	<u>SMC advice</u> <u>SPC link</u>
Levetiracetam 250, 500, 750 & 100mg tablets and 100mg/ml oral solution (Keppra [®]) - <i>Resubmission</i>	Adjunctive therapy in primary generalised tonic-clonic seizures (PGTC)	GPs may prescribe under the direction of paediatrics or adult neurology TAPG review June 08	<u>SMC advice</u> <u>SPC link</u>
Levetiracetam 250, 500, 750 & 100mg tablets and 100mg/ml oral solution (Keppra [®]) - <i>Resubmission</i>	Monotherapy in partial onset seizures	GPs may prescribe under the direction of paediatrics or adult neurology. TAPG review June 08	<u>SMC advice</u> <u>SPC link</u>
Losartan 100mg/ hydrochlorothiazide 12.5mg tablet (Cozaar-Comp 100/12.5 [®])	Treatment of hypertension in patients whose blood pressure is not adequately controlled on hydrochlorothiazide or losartan monotherapy	Non-Formulary	<u>SMC advice</u> <u>SPC link</u>

Medicine	Indication	Local recommendation category	Comments and useful links
Mesalazine mr tablet 800mg (Asacol [®]) - <i>Abbreviated submission</i>	Moderate acute exacerbations of ulcerative colitis	Formulary	<u>SMC advice</u> <u>SPC link</u>
Mesalazine mr tablet 800mg (Asacol [®]) - <i>Abbreviated submission</i>	Mild acute exacerbations of ulcerative colitis	Formulary	<u>SMC advice</u> <u>SPC link</u>
Mesalazine mr tablet 800mg (Asacol [®]) - <i>Abbreviated submission</i>	Maintenance of remission in ulcerative colitis and Crohn's ileo-colitis	Formulary	<u>SMC advice</u> <u>SPC link</u>
Mesalazine 1200mg gastro-resistant, prolonged release tablet (Mezavant XL [®]) Abbreviated submission	Induction of remission in mild to moderate, active ulcerative colitis and for maintenance of remission.	Non -Formulary	<u>SMC advice</u> <u>SPC link</u>
Pemetrexed (Alimta [®]) - Resubmission	Monotherapy for treatment of patients with locally advanced or metastatic non-small cell lung cancer after prior chemotherapy	Not recommended	<u>SMC advice</u>
Salmeterol/fluticasone 50/500 micrograms inhaler (Seretide 500 Accuhaler [®])	Symptomatic treatment of patients with COPD with FEV ₁ 50 to <60% predicted	Not recommended	<u>SMC advice</u>
Telbivudine 600mg film- coated tablets (Sebivo [®])	Treatment of chronic hepatitis B	Pending AMG decision and local protocol for hepatitis B	<u>SMC advice</u> <u>SPC link</u>
Trabectedin (Yondelis [®]) - Non submission	Treatment of patients with advanced soft tissue sarcoma	Not recommended	SMC advice
Valsartan 320mg tablet (Diovan [®]) - <i>Abbreviated</i> <i>submission</i>	Treatment of hypertension	Non-Formulary	<u>SMC advice</u> <u>SPC link</u>
Zoledronic acid, 5mg solution for infusion (Aclasta [®])	Treatment of osteoporosis in post-menopausal women at increased risk of fractures.	HOSPITAL ONLY – medicine, care of the elderly	<u>SMC advice</u> <u>SPC link</u>

TAPG Update

	TAPG section	Drug(s)/topic	Changes	
1.5	Treatment of inflammatory bowel disease	Mesalazine	Mesalazine mr tablet 800mg (Asacol [®])* added.	
2.1	Cardiac Glycosides	Digoxin	Dosage for less urgent digitalisation minor change. Expanding prescribing note including caution with drugs that increase digoxin concentrations, examples given.	
2.2	Diuretics	Thiazide diuretics	Links to Management of Hypertension guideline and A/CD algorithm for hypertension inserted.	
		Loop diuretics	Furosemide change to dosage instructions. Bumetanide- note added as 2 nd choice in confirmed heart failure and resistant fluid overload.	
		Spironolactone	Note added that spironolactone may be used at Step 4 in A/CD algorithm for hypertension and link inserted.	
		Eplerenone	Tayside recommendation and statement within TAPG updated in line with SMC recommendation.	
2.3	Anti-arrhythmics	Permanent atrial fibrillation	Link to NHS Tayside protocol for treatment of atrial fibrillation inserted. Atenolol removed as beta-blocker listed for rate control in permanent atrial fibrillation.	
		Paroxysmal atrial fibrillation/supraventricular tachycardias	Expanded prescribing note and link to SIGN No.94 inserted.	

2.4 Beta-blockers Bisoprolol Highlighted as 1 st choice beta-blocker and a instructions added. Expanded prescribing note including statem beta-blockers no longer preferred for routin treatment of uncomplicated hypertension a A/CD algorithm inserted. Link to SIGN guidelines No. 93, 94, 95 and 2.5 Drugs affecting the renin-angiotensin system and alpha-adrenoceptor blocking drugs Alpha-adrenoceptor blocking drugs Doxazosin added to section, along with dos instructions and link to A/CD algorithm inserted. Alpha-adrenoceptor blocking drugs Alpha-adrenoseptor blocking drugs Distructions and link to A/CD algorithm inserted. Alpha-adrenoseptor blocking drugs Alpha-adrenoseptor blocking drugs Distructions and link to A/CD algorithm inserted. Instructions and link to A/CD algorithm inserted. Enalapril removed. Paragraph on diabetic nephropathy update Angiotensin – II receptor antagonists Angiotensin – II receptor antagonists. Expanded prescribing note on indication for – II receptor antagonists.	nent that e initial nd link to <u>96 inserted.</u> sage hypertension.
2.5 Drugs affecting the renin-angiotensin system and alpha-adrenoceptor blocking drugs Alpha-adrenoceptor blocking drugs Data A/CD algorithm inserted. Link to SIGN guidelines No. 93, 94, 95 and Doxazosin added to section, along with dos instructions and link to A/CD algorithm inserted. Enalapril removed. Paragraph on diabetic nephropathy update Angiotensin – II receptor	e initial nd link to <u>96 inserted.</u> sage hypertension.
2.5 Drugs affecting the renin-angiotensin system and alpha-adrenoceptor blocking drugs Alpha-adrenoceptor blocking drugs Dalgorithm inserted. Link to SIGN guidelines No. 93, 94, 95 and Doxazosin added to section, along with dos instructions and link to A/CD algorithm inserted. Enalapril removed. Paragraph on diabetic nephropathy update Angiotensin – II receptor	e initial nd link to <u>96 inserted.</u> sage sypertension.
2.5 Drugs affecting the renin-angiotensin system and alpha-adrenoceptor blocking drugs Alpha-adrenoceptor blocking drugs Doxazosin added to section, along with dos instructions and link to A/CD algorithm inserted. Link to A/CD algorithm inserted. Enalapril removed. Paragraph on diabetic nephropathy update Angiotensin – II receptor	nd link to 96 inserted. sage hypertension.
2.5 Drugs affecting the renin-angiotensin system and alpha-adrenoceptor blocking drugs Alpha-adrenoceptor blocking drugs Doxazosin added to section, along with dos instructions and link to A/CD algorithm inserted. Enalapril removed. Paragraph on diabetic nephropathy update Angiotensin – II receptor	96 inserted. sage hypertension.
2.5 Drugs affecting the renin-angiotensin system and alpha-adrenoceptor blocking drugs Alpha-adrenoceptor blocking drugs Doxazosin added to section, along with dos instructions and link to A/CD algorithm for h Link to A/CD algorithm inserted. Enalapril removed. Paragraph on diabetic nephropathy update Angiotensin – II receptor	sage hypertension.
2.5 Drugs affecting the renin-angiotensin system and alpha- adrenoceptor blocking drugs Alpha-adrenoceptor blocking drugs Doxazosin added to section, along with dos instructions and link to A/CD algorithm for h Link to A/CD algorithm inserted. Enalapril removed. Paragraph on diabetic nephropathy update Alpha-adrenoceptor blocking drugs Alpha-adrenoceptor blocking drugs Doxazosin added to section, along with dos instructions and link to A/CD algorithm for h Enalapril removed. Paragraph on diabetic nephropathy update	sage hypertension.
renin-angiotensin system and alpha- adrenoceptor blocking drugs drugs instructions and link to A/CD algorithm for h Link to A/CD algorithm inserted. Enalapril removed. Paragraph on diabetic nephropathy update Angiotensin – II receptor Expanded prescribing note on indication for	hypertension.
system and alpha- adrenoceptor blocking drugs ACE inhibitors Link to A/CD algorithm inserted. Enalapril removed. Paragraph on diabetic nephropathy update Angiotensin – II receptor Expanded prescribing note on indication for	
adrenoceptor blocking drugs Enalapril removed. Angiotensin – II receptor Expanded prescribing note on indication for	
drugs Paragraph on diabetic nephropathy update Angiotensin – II receptor Expanded prescribing note on indication for	
Angiotensin – II receptor Expanded prescribing note on indication for	
	d.
antagonists – II receptor antagonists.	r angiotensin
	-
Candesartan highlighted as 1 st choice sarta	an in heart
failure (and hypertension) if ACE inhibitor n	ot tolerated.
Expanded prescribing note on diabetic nep	hropathy
including irbesartan highlighted as 1 st choic	e sartan for
diabetic renal disease if ACE inhibitor not to	
2.6 Nitrates, calcium- Nitrates Dosage instructions for glyceryl trinitrate su	ıblingual
channel blockers and tablets added.	°
potassium-channel Isosorbide mononitrate dosage instructions	updated.
activators Calcium-channel blockers Expanded prescribing note and links to Ma	nagement of
Stable Angina and Management of Hyperte	ension
guidelines.	
Potassium-channel activators Prescribing note added.	
6.1 Drugs used in diabetes Rosiglitazone Updated warning for rosiglitazone from the	MHRA.
Contraindicated in patients with acute coro	
syndrome & not recommended in pts with i	
heart disease or peripheral arterial disease	

* SMC accepted medicine

Eplerenone update

Local advice for the use of eplerenone for heart failure post-MI has been updated in line with SMC recommendations.

Eplerenone is now locally recommended under the direction of a cardiologist, in addition to standard therapy, to reduce the risk of cardiovascular mortality and morbidity post-MI in stable patients with left ventricular ejection fraction \leq 40% and clinical signs of heart failure.

Further information is available within <u>Section 2.2</u> of the Tayside Area Prescribing Guide.

Minor Ailments Scheme Formulary

The NHS Tayside Minor Ailments Scheme Formulary for use in community pharmacy has been updated by community pharmacists from Tayside. It can be found by linking from the Tayside Area Prescribing Guide website. <u>Click here</u>

Oramorph[®] liquid Unit Dose Vials (UDVs) discontinuation

All strengths of oramorph UDVs, 10mg/5ml, 30mg/5ml and 100mg/5ml are to be discontinued at the end of March 2008. Oramorph 10mg /5ml, 100ml, 300ml, 500ml and oramorph 100mg/5ml, 30ml, 120ml are still available.

Forthcoming SMC Advice

Local implementation of SMC recommendations is taken forward by the Tayside Medicines Governance Unit. This bulletin is based on evidence available to the Tayside Medicines Governance Unit at time of publication and is covered by the Disclaimer and Terms & Conditions of use and access to the NHS Tayside Drug and Therapeutics Committee website (www.nhstaysideadtc.scot.nhs.uk).